Why choose us?

AstraZeneca is committed to licensing. We believe that successful collaborations with leading academic centers and biotechnology and pharmaceutical companies are an important source of innovative products and technologies and play a key role in strengthening our portfolio and complementing our in-house capabilities. Your partnering opportunity will receive prompt and considered attention and will be managed efficiently by our global evaluation process. We will provide constructive feedback on a timely basis.

What do we offer a partner?

• A history of innovative and successful partnering
• A licensing organization focused on meeting needs of licensors
• A corporate commitment to in-licensed assets
• A world-class research, clinical development, and regulatory organization
• A strong sales force and demonstrated marketing expertise
• Leadership positions in therapeutic areas of focus
• A Record of Successful Product Life Cycle Management
• A culture which recognizes the competence, motivation, and performance of its people and collaborative partners

We are committed to developing mutually successful partnership agreements. Our philosophy in such partnerships is to ensure that joint benefit is derived from enhanced market opportunity.

AstraZeneca-leading innovation in world healthcare

AstraZeneca has a world-class record of successful R&D aimed at generating a flow of new prescription medicines and preserving or enhancing the competitive advantages and market position of existing products. Research is strategically focused on important commercial targets and on real medical needs within several therapy areas, including gastrointestinal, oncology, cardiovascular, respiratory, central nervous system, infection, pain, and inflammation.

Our success ratio of bringing new products to market is among the best in the industry. We have set challenging and ambitious targets for each therapy area for the next 10 years, with the goal of achieving the following world-wide market positions:

• No. 1 in gastrointestinal
• No. 1 in oncology
• No. 1 in cardiovascular
• No. 1 in pain control
• No. 2 in respiratory
• 10% market share in central nervous system
• Top 3 in serious hospital infections

Successful partnering agreements will be key to achieving our portfolio objectives.